Program

Wednesday, January 31, 2018

8:30 a.m. | Registration Opens

10:00 a.m. | Plenary Lecture

  • Role of very low carb diets in T1D management (Belinda Lennerz, M.D., Ph.D., Boston Children's Hospital)
     


10:45 a.m. | Session 1: Advances in Beta Cell Regeneration

  • Insulitis and residual beta cell mass in T1D (Martha Campbell-Thompson, DVM, Ph.D., University of Florida College of Medicine)
  • Cell adhesion and pancreas organogenesis: New insights on old adhesion molecules (Hung-Ping Shih, Ph.D., City of Hope)
  • Alpha to beta cell transdifferentiation (Fabrizio Thorel, Ph.D., Universite de Geneve)
  • What limits beta cell regeneration? (Yuval Dor, Ph.D., The Hebrew University-Hadassah Medical School)
  • Do human islets respond to gastrin? (Young Investigator Talk) (Ayelet Lenz, Ph.D., City of Hope)
     


1:20 p.m. | Session 2: nPOD and HiRN Updates

  •  nPOD updates (Mark Atkinson, Ph.D., University of Florida College of Medicine)
  • HiRN updates (Maike Sander, M.D., University of California, San Diego)
     


2:50 p.m. | Plenary Lecture

  • Combination therapy with ATG and GCSF in type 1 diabetes (Michael Haller, M.D., University of Florida College of Medicine)
     


5 p.m. | Keynote Dinner Lecture

  • Omics of diabetes – Personalized diagnosis and treatments (Michael Snyder, Ph.D., Stanford University)
     

Thursday, February 1, 2018

8 a.m. | Rachmiel Levine Award Lecture

8:45 a.m. | Session 1: Encapsulation and Mechanical Immunoprotective Approaches in Beta Cell Replacement

  • Macroencapsulation approaches (Evert Kroon, Ph.D., ViaCyte, Inc.)
  • Biosynthetic materials for islet encapsulation and transplantation (Andres Garcia, Ph.D., Georgia Institute of Technology)
  • Biological scaffolds: Miami Omental islet transplant (Rodolfo Alejandro, M.D., University of Miami)
  • Mechanical immune protection of transplant islets: Clinical perspective (Olle Korsgren, M.D., Ph.D., University of Uppsala)
     

11:05 a.m. | Session 2: Control of Beta Cell Function

  • Control of insulin secretion by cytochrome C and signaling in impaired islets (Ian Sweet, Ph.D., University of Washington School of Medicine)
  • Neural control of beta cell function (Sarah Stanley, MBBCh, Ph.D., Icahn School of Medicine at Mount Sinai)
  • Islet cell heterogeneity: Hubs and spokes (Guy Rutter, Ph.D., Imperial College London)
  • Pumping up beta cell function and durability (Debbie Thurmond, Ph.D., City of Hope)
     

2:30 p.m. | Round Table Discussion

  • Virus, B-cells, beta-cell function as endpoint in immunotherapy, autoimmunity vs. innate immunity (Panel Discussion to include: Carla Greenbaum, M.D.; David Harlan, M.D.; Olle Korsgren, M.D., Ph.D.; Bart Roep, Ph.D.; and Matthias von Herrath, M.D.)
     

4 p.m. | Session 3: Epigenetics of Diabetes

  • Epigenetics and pancreatic beta cell maturation (Sangeeta Dhawan, Ph.D., City of Hope)
  • Epigenetics in diabetic complications and metabolic memory (Rama Natarajan, Ph.D., City of Hope)
  • The epigenetic effects of metabolic syndrome on adipose tissue (Matteo Pellegrini, Ph.D., University of California, Los Angeles)
  • Acute heritable epigenetic changes induced by physical exercise (Romain Barrès, Ph.D., University of Copenhagen)
     

6 p.m. | Poster Session
 

Friday, February 2, 2018

8 a.m. | Plenary Lecture

  • Cellular energy sensing and metabolism: Implications for treating type 2 diabetes (Gregory Steinberg, Ph.D., McMaster University)
     

8:45 a.m. | Session 1: Metabolism in Obesity and Diabetes

  • FGF21 regulates metabolism through adipose dependent and independent mechanisms (Matthew Potthoff, Ph.D., University of Iowa)
  • RAGE, lipolysis and the immunometabolic sphere in the regulation of energy expenditure (Ann Marie Schmidt, M.D., NYU School of Medicine)
  • Adipose tissue function as a determinant of liver and hypothalamic function (Christoph Buettner, M.D., Ph.D., Icahn School of Medicine at Mount Sinai)
  • Paracrine signaling circuits within adipose tissues in metabolic disease (Michael Czech, Ph.D., University of Massachusetts School of Medicine)
     

11:05 a.m. | Session 2: TrialNet and ITN Updates

  • TrialNet updates on disease modifying therapy in T1D (Carla Greenbaum, M.D., Benaroya Research Institute)
  • ITN T1D mechanistic updates (Elisavet Serti, Ph.D., Immune Tolerance Network)
     

2 p.m. | Session 3: Molecular and Cellular Immunology of Diabetes

  • Insights from the type 1 diabetes pancreas (Sarah Richardson, Ph.D., University of Exeter Medical School)
  • Implementation of cellular therapies: A Tans Pacific view (Jaap-Jan Zwaginga, M.D., Ph.D., Leiden University Medical Center)
  • Loss of IDO in human pre-diabetes (Florence Anquetil-Besnard, Ph.D., La Jolla Institute for Allergy and Immunology)
  • Association of serum micro RNAs with islet autoimmunity, disease progression and metabolic impairment in relatives of T1D (Alberto Pugliese, M.D., University of Miami)
  • Anti CD6 to circumvent autoimmunity in T1D (Young Investigator Talk) (Jose Enrique Montero Casimiro, M.D., Ph.D., City of Hope)
     

4:35 p.m. | Session 4: Tregs and Diabetes

  • Measuring and manipulating Tregs in T1D (Timothy Tree, Ph.D., King’s College London)
  • Haploidentical mixed chimerism for cure of new onset T1D in preclinical models (Defu Zeng, M.D., City of Hope)
  • Clinical trials of Treg therapy of autoimmune diseases and transplantation (Qizhi Tang, Ph.D., University of California, San Francisco)

 

Saturday, February 3, 2018

8 a.m. | Arthur Riggs Award Lecture

 

8:45 a.m. | Session 1: Personalized Medicine

  • Precision diabetes: Learning from monogenic diabetes (Kashyap Patel, MRCP, Ph.D., University of Exeter Medical School)
  • Identification of RUNX1 as a mediator of aberrant angiogenesis in proliferative diabetic retinopathy (Leo Kim, M.D., Ph.D., Harvard Medical School)
  • Genome wide physical activity interactions in adiposity (Mariaelisa Graff, Ph.D., University of North Carolina at Chapel Hill)
  • Vetting and advancing individualized medicine: Issues and strategies (Nicholas Schork, Ph.D., The Translational Genomics Research Institute)
     

11:05 a.m. | Session 2: Extracellular Vesicles and Diabetes (1)

  • The exosome paradigm of intracellular communication (Philip Stahl, Ph.D., Washington University School of Medicine)
  • Extracellular RNA as a means to monitor health and disease (Kendall Van Keuren-Jensen, Ph.D., The Translational Genomics Research Institute)
  • MSC-derived EV attenuate immune responses in two autoimmune murine models: T1D and Uveoretinitis (Ryang Hwa Lee, Ph.D., Texas A&M University)
     

1 p.m. | Session 3: Extracellular Vesicles and Diabetes (2)

  • Exosome induced beta cell expansion (Michael German, M.D., University of California, San Francisco)
  • Human islets release T1D autoantigens in exosomes together with cytokine-induced enhances in immunity (Edward Phelps, Ph.D., University of Florida)
  • Tissue specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue (Prashanth Vallabhajosyula, M.D., Hospital of the University of Pennsylvania)